Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.48 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18519770 | 0.95 | EHMT2 (0.50) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL14868086 | 0.89 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL20648097 | 0.88 | EHMT2 (0.46) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL11822538 | 0.87 | EHMT2 (0.64) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL2607950 | 0.85 | HDAC1 (0.45) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL11835311 | 0.85 | EHMT2 (0.61) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL12584040 | 0.85 | EHMT2 (0.61) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL11834639 | 0.85 | EHMT2 (0.61) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL11821186 | 0.85 | EHMT2 (0.61) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 | |
| SCHEMBL11834472 | 0.85 | EHMT2 (0.61) | EHMT2EHMT1APOBEC3GHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3428147-A1 | POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2019-01-16 | — | — | EP | disclosed |
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | LEHMANN LUTZ (DE) | 2012-03-15 | — | — | US | disclosed |
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | LEHMANN LUTZ (DE) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | CYP4B1, CYP2B6, UGT2B7 | EHMT2 4613/4885EHMT1 4652/4885APOBEC3G 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.